# Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

> **NCT02698384** · — · TERMINATED · sponsor: **Ipsen** · enrollment: 4 (actual)

## Conditions studied

- Acromegaly

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02698384
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated early due to insufficient potential for recruitment.
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698384, "Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02698384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*